Discovery of 1 H-indole-2-carboxamides as novel inhibitors of the androgen receptor binding function 3 (BF3)

Journal of Medicinal Chemistry

Volumn 57, Issue 15, 2014, Pages 6867-6872

  Ban, Fuqiang ^a   Leblanc, Eric ^a   Li, Huifang ^a   Munuganti, Ravi S N ^a   Frewin, Kate ^a   Rennie, Paul S ^a   Cherkasov, Artem ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

1H INDOLE 2 CARBOXAMIDE DERIVATIVE; 5 FLUORO N (FURAN 2 YLMETHYL) N ISOPROPYL 1H INDOLE 2 CARBOXAMIDE; 5 FLUORO N ISOPROPYL N [(5 METHYLFURAN 2 Y)METHYL] 1H INDOLE 2 CARBOXAMIDE; 6 FLUORO N (FURAN 2 YLMETHYL) N ISOPROPYL 1H INDOLE 2 CARBOXAMIDE; 6 FLUORO N ISOPROPYL N [(5 METHYLFURAN 2 YL)METHYL] 1H INDOLE 2 CARBOXAMIDE; 7 FLUORO N ISOPROPYL N [(5 METHYLFURAN 2 YL)METHYL] 1H INDOLE 2 CARBOXAMIDE; AMIDE; ANDROGEN RECEPTOR; ANDROGEN RECEPTOR BINDING FUNCTION 3; ANTIANDROGEN; ANTINEOPLASTIC AGENT; ENZALUTAMIDE; N (FURAN 2 YLMETHYL) N ISOPROPYL 5 (TRIFLUOROMETHYL) 1H INDOLE 2 CARBOXAMIDE; N (FURAN 2 YLMETHYL) N ISOPROPYL 5 METHYL 1H INDOLE 2 CARBOXAMIDE; N (FURAN 2 YLMETHYL) N ISOPROPYL 6 METHYL 1H INDOLE 2 CARBOXAMIDE; N ISOPROPYL 5 METHYL [(5 METHYLFURAN 2 YL)METHYL] 1H INDOLE 2 CARBOXAMIDE; N ISOPROPYL 6 METHYL N [(5 METHYLFURAN 2 YL)METHYL] 1H INDOLE 2 CARBOXAMIDE; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG; INDOLE DERIVATIVE; MOLECULAR LIBRARY;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BINDING SITE; CASTRATION RESISTANT PROSTATE CANCER; CELL PROLIFERATION; CHEMICAL STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; LNCAP CELL LINE; MOLECULAR DOCKING; MOLECULAR LIBRARY; PHARMACOPHORE; PROSTATE CANCER CELL LINE; PROTEIN EXPRESSION; CHEMISTRY; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; MALE; METABOLISM; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; STRUCTURE ACTIVITY RELATION; SYNTHESIS; TUMOR CELL LINE;

ALLOSTERIC SITE; AMIDES; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INDOLES; MALE; MODELS, MOLECULAR; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RECEPTORS, ANDROGEN; SMALL MOLECULE LIBRARIES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84906093250     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm500684r     Document Type: Article

References (34)

1. Huggins, C.; Hodges, C. V. Studies on prostatic cancer I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate Cancer Res. 1941, 1, 293-297
2. Schmidt, L. J.; Tindall, D. J. Androgen receptor: past, present and future Curr. Drug Targets 2013, 14, 401-407
3. Feldman, B. J.; Feldman, D. The development of androgen-independent prostate cancer Nat. Rev. Cancer 2001, 1, 34-45
4. Oudard, S. Progress in emerging therapies for advanced prostate cancer Cancer Treat. Rev. 2013, 39, 275-289
5. Tran, C.; Ouk, S.; Clegg, N. J.; Chen, Y.; Watson, P. A.; Arora, V.; Wongvipat, J.; Smith-Jones, P. M.; Yoo, D.; Kwon, A.; Wasielewska, T.; Welsbie, D.; Chen, C. D.; Higano, C. S.; Beer, T. M.; Hung, D. T.; Scher, H. I.; Jung, M. E.; Sawyers, C. L. Development of a second-generation antiandrogen for treatment of advanced prostate cancer Science 2009, 324, 787-790
6. Guerrero, J.; Alfaro, I. E.; Gomez, F.; Protter, A. A.; Bernales, S. Enzalutamide, an androgen receptor signaling inhibitor, induces tumor regression in a mouse model of castration-resistant prostate cancer Prostate 2013, 73, 1291-1305
7. Josan, J. S.; Katzenellenbogen, J. A. Designer antiandrogens join the race against drug resistance eLife 2013, 2, 1-4
8. Korpal, M.; Korn, J. M.; Gao, X.; Rakiec, D. P.; Ruddy, D. A.; Doshi, S.; Yuan, J.; Kovats, S. G.; Kim, S.; Cooke, V. G.; Monahan, J. E.; Stegmeier, F.; Roberts, T. M.; Sellers, W. R.; Zhou, W.; Zhu, P. An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide) Cancer Discovery 2013, 3, 1030-1043
9. Karantanos, T.; Corn, P. G.; Thompson, T. C. Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches Oncogene 2013, 32, 5501-5511
10. Scher, H. I.; Sawyers, C. L. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis J. Clin. Oncol. 2005, 23, 8253-8261
11. Andersen, R. J.; Mawji, N. R.; Wang, J.; Wang, G.; Haile, S.; Myung, J. K.; Watt, K.; Tam, T.; Yang, Y. C.; Banuelos, C. A.; Williams, D. E.; McEwan, I. J.; Wang, Y.; Sadar, M. D. Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor Cancer Cell 2010, 17, 535-546
12. Caboni, L.; Kinsella, G. K.; Blanco, F.; Fayne, D.; Jagoe, W. N.; Carr, M.; Williams, D. C.; Meegan, M. J.; Lloyd, D. G. "True" antiandrogens-selective non-ligand-binding pocket disruptors of androgen receptor-coactivator interactions: novel tools for prostate cancer J. Med. Chem. 2012, 55, 1635-1644
13. De Leon, J. T.; Iwai, A.; Feau, C.; Garcia, Y.; Balsiger, H. A.; Storer, C. L.; Suro, R. M.; Garza, K. M.; Lee, S.; Kim, Y. S.; Chen, Y.; Ning, Y. M.; Riggs, D. L.; Fletterick, R. J.; Guy, R. K.; Trepel, J. B.; Neckers, L. M.; Cox, M. B. Targeting the regulation of androgen receptor signaling by the heat shock protein 90 cochaperone FKBP52 in prostate cancer cells Proc. Natl. Acad. Sci. U.S.A. 2011, 108, 11878-11883
14. Estebanez-Perpina, E.; Arnold, A. A.; Nguyen, P.; Rodrigues, E. D.; Mar, E.; Bateman, R.; Pallai, P.; Shokat, K. M.; Baxter, J. D.; Guy, R. K.; Webb, P.; Fletterick, R. J. A surface on the androgen receptor that allosterically regulates coactivator binding Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 16074-16079
15. Grosdidier, S.; Carbo, L. R.; Buzon, V.; Brooke, G.; Nguyen, P.; Baxter, J. D.; Bevan, C.; Webb, P.; Estebanez-Perpina, E.; Fernandez-Recio, J. Allosteric conversation in the androgen receptor ligand-binding domain surfaces Mol. Endocrinol. 2012, 26, 1078-1090
16. Gunther, J. R.; Parent, A. A.; Katzenellenbogen, J. A. Alternative inhibition of androgen receptor signaling: peptidomimetic pyrimidines as direct androgen receptor/coactivator disruptors ACS Chem. Biol. 2009, 4, 435-440
17. Joseph, J. D.; Wittmann, B. M.; Dwyer, M. A.; Cui, H.; Dye, D. A.; McDonnell, D. P.; Norris, J. D. Inhibition of prostate cancer cell growth by second-site androgen receptor antagonists Proc. Natl. Acad. Sci. U.S.A. 2009, 106, 12178-12183
18. Lack, N. A.; Axerio-Cilies, P.; Tavassoli, P.; Han, F. Q.; Chan, K. H.; Feau, C.; LeBlanc, E.; Guns, E. T.; Guy, R. K.; Rennie, P. S.; Cherkasov, A. Targeting the binding function 3 (BF3) site of the human androgen receptor through virtual screening J. Med. Chem. 2011, 54, 8563-8573
19. Munuganti, R. S.; Leblanc, E.; Axerio-Cilies, P.; Labriere, C.; Frewin, K.; Singh, K.; Hassona, M. D.; Lack, N. A.; Li, H.; Ban, F.; Tomlinson Guns, E.; Young, R.; Rennie, P. S.; Cherkasov, A. Targeting the binding function 3 (BF3) site of the androgen receptor through virtual screening. 2. development of 2-((2-phenoxyethyl)thio)-1 H-benzimidazole derivatives J. Med. Chem. 2013, 56, 1136-1148
20. Myung, J. K.; Banuelos, C. A.; Fernandez, J. G.; Mawji, N. R.; Wang, J.; Tien, A. H.; Yang, Y. C.; Tavakoli, I.; Haile, S.; Watt, K.; McEwan, I. J.; Plymate, S.; Andersen, R. J.; Sadar, M. D. An androgen receptor N-terminal domain antagonist for treating prostate cancer J. Clin. Invest. 2013, 123, 2948-2960
21. Ravindranathan, P.; Lee, T.-K.; Yang, L.; Centenera, M. M.; Butler, L.; Tilley, W. D.; Hsieh, J.-T.; Ahn, J.-M.; Raj, G. V. Peptidomimetic targeting of critical androgen receptor-coregulator interactions in prostate cancer Nat. Commun. 2013, 4, 1923
22. Jehle, K.; Cato, L.; Neeb, A.; Muhle-Goll, C.; Jung, N.; Smith, E. W.; Buzon, V.; Carbo, L. R.; Estebanez-Perpina, E.; Schmitz, K.; Fruk, L.; Luy, B.; Chen, Y.; Cox, M. B.; Brase, S.; Brown, M.; Cato, A. C. Coregulator control of androgen receptor action by a novel nuclear receptor-binding motif J. Biol. Chem. 2014, 289, 8839-8851
23. Arkin, M. R.; Wells, J. A. Small-molecule inhibitors of protein-protein interactions: progressing towards the dream Nat. Rev. Drug Discovery 2004, 3, 301-317
24. Boobbyer, D. N. A.; Goodford, P. J.; McWhinnie, P. M.; Wade, R. C. New hydrogen-bond potentials for use in determining energetically favorable binding sites on molecules of known structure J. Med. Chem. 1989, 32, 1083-1094
25. Goodford, P. J. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules J. Med. Chem. 1985, 28, 849-857
26. MOE, 2010. http://www.chemcomp.com/.
27. Screening compounds, 2012. http://www.emolecules.com/.
28. Schrodinger suite of drug design software, 2012, www.schrodinger.com.
29. Tavassoli, P.; Snoek, R.; Ray, M.; Rao, L. G.; Rennie, P. S. Rapid, non-destructive, cell-based screening assays for agents that modulate growth, death, and androgen receptor activation in prostate cancer cells Prostate 2007, 67, 416-426
30. Balk, S. P.; Ko, Y. J.; Bubley, G. J. Biology of prostate-specific antigen J. Clin. Oncol. 2003, 21, 383-391
31. Matsumoto, H.; Yamamoto, Y.; Shiota, M.; Kuruma, H.; Beraldi, E.; Matsuyama, H.; Zoubeidi, A.; Gleave, M. Cotargeting androgen receptor and clusterin delays castrate-resistant prostate cancer progression by inhibiting adaptive stress response and AR stability Cancer Res. 2013, 73, 5206-5217
32. Kuruma, H.; Matsumoto, H.; Shiota, M.; Bishop, J.; Lamoureux, F.; Thomas, C.; Briere, D.; Los, G.; Gleave, M.; Fanjul, A.; Zoubeidi, A. A novel antiandrogen, compound 30, suppresses castration-resistant and MDV3100-resistant prostate cancer growth in vitro and in vivo Mol. Cancer Ther. 2013, 12, 567-576
33. Horoszewicz, J.; Leong, S.; Chu, T.; Wajsman, Z.; Friedman, M.; Papsidero, L.; Kim, U.; Chai, L.; Kakati, S.; Arya, S.; Sandberg, A. The LNCaP cell line-a new model for studies on human prostatic carcinoma Prog. Clin. Biol. Res. 1980, 37, 115-132
34. Bohl, C. E.; Miller, D. D.; Chen, J.; Bell, C. E.; Dalton, J. T. Structural basis for accommodation of nonsteroidal ligands in the androgen receptor J. Biol. Chem. 2005, 280, 37747-37754